La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BiomX a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BiomX..

BiomX (AMEX:PHGE) Azioni, Quote.MetaTitle.option-chain

BiomX

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evogene

Imunon

Immuron Limited - American Depositary Shares

Immuron

Mustang Bio

Marker Therapeutics

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

BiomX (PHGE) Previsione

Notizie

Utili

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Comments

BiomX Catena di Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO